JPH10502664A - 硬組織刺激剤 - Google Patents
硬組織刺激剤Info
- Publication number
- JPH10502664A JPH10502664A JP8504955A JP50495596A JPH10502664A JP H10502664 A JPH10502664 A JP H10502664A JP 8504955 A JP8504955 A JP 8504955A JP 50495596 A JP50495596 A JP 50495596A JP H10502664 A JPH10502664 A JP H10502664A
- Authority
- JP
- Japan
- Prior art keywords
- chitosan
- hard tissue
- heparin
- implant
- sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001661 Chitosan Polymers 0.000 claims abstract description 58
- 239000007943 implant Substances 0.000 claims abstract description 35
- 229960002897 heparin Drugs 0.000 claims abstract description 34
- 229920000669 heparin Polymers 0.000 claims abstract description 33
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 32
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 31
- 210000001519 tissue Anatomy 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 22
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 17
- 150000004676 glycans Chemical class 0.000 claims abstract description 17
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 17
- 239000005017 polysaccharide Substances 0.000 claims abstract description 17
- 229920002971 Heparan sulfate Polymers 0.000 claims abstract description 13
- 230000004936 stimulating effect Effects 0.000 claims abstract description 10
- 229960000633 dextran sulfate Drugs 0.000 claims abstract description 9
- 230000017423 tissue regeneration Effects 0.000 claims abstract description 8
- 238000010883 osseointegration Methods 0.000 claims abstract description 7
- 230000008929 regeneration Effects 0.000 claims abstract description 7
- 238000011069 regeneration method Methods 0.000 claims abstract description 7
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 5
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 5
- 238000010348 incorporation Methods 0.000 claims abstract description 4
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 24
- 229910052719 titanium Inorganic materials 0.000 claims description 17
- 239000010936 titanium Substances 0.000 claims description 17
- 238000006640 acetylation reaction Methods 0.000 claims description 10
- 239000011324 bead Substances 0.000 claims description 10
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 229920002567 Chondroitin Polymers 0.000 claims description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims 1
- 238000007654 immersion Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000010408 film Substances 0.000 description 15
- 239000012528 membrane Substances 0.000 description 13
- 230000007547 defect Effects 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 230000011164 ossification Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000002188 osteogenic effect Effects 0.000 description 6
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 6
- 210000002082 fibula Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 208000006735 Periostitis Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000021736 acetylation Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000003460 periosteum Anatomy 0.000 description 4
- 210000003625 skull Anatomy 0.000 description 4
- 229920002101 Chitin Polymers 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229940094517 chondroitin 4-sulfate Drugs 0.000 description 3
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 3
- 238000002316 cosmetic surgery Methods 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000013543 active substance Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002745 epiphysis Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000002454 frontal bone Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 101100120045 Bos taurus FGF1 gene Proteins 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- -1 heparin ion Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000966 temporal muscle Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Chemical Or Physical Treatment Of Fibers (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.硬組織の再生を剌激することができる作用剤を製造するための、キトサンと 、それに固定された、ヘパリン、ヘパラン硫酸、コンドロイチン硫酸およびデキ ストラン硫酸から選ばれる多糖の使用。 2.硬組織の再生が骨組織のような硬組織内のインプラントとの関連において刺 激される、請求項1に記載の使用。 3.多糖がイオン結合によってキトサンに固定される、請求項1または2に記載 の使用。 4.多糖が共有結合によってキトサンに固定される、請求項1または2に記載の 使用。 5.多糖がヘパリンまたはヘパラン硫酸である、請求項1〜4のいずれか1つに 記載の使用。 6.作用剤が粉末または溶液の形である、請求項1〜5のいずれか1つに記載の 使用。 7.作用剤がゲルの形である、請求項1〜5のいずれか1つに記載の使用。 8.作用剤がビーズの形である、請求項1〜5のいずれか1つに記載の使用。 9.キトサンが多くても約90%、好ましくは多くても約50%のN-アセチル化 度を有する、請求項1〜8のいずれか1つに記載の使用。 10.キトサンが約25%より低いN-アセチル化度を有する、請求項9に記載の使 用。 11.インプラントがチタンから構成される、請求項2〜10のいずれか1つに記載 の使用。 12.キトサンと、それに固定された、ヘパリン、ヘパラン硫酸、コンドロイチン 硫酸およびデキストラン硫酸から選ばれる多糖と、からなる作用剤を、剌激有効 量で適当な部位に適用することを特徴とする、硬組織の再生を剌激および/また は促進する方法。 13.再生がオセオインテグレーション(osseointegration)に関連している、請求 項12に記載の方法。 14.オセオインテグレーションが骨組織のような硬組織内のインプラントとの関 連において行われる、請求項13に記載の方法。 15.作用剤が粉末の形で適用される、請求項12〜14のいずれか1つに記載の方法 。 16.作用剤がゲルの形で適用される、請求項12〜14のいずれか1つに記載の方法 。 17.多糖がヘパリンまたはヘパラン硫酸により構成される、請求項12〜16のいず れか1つに記載の方法。 18.作用剤が、硬組織に組み込もうとするインプラントの部分をキトサンと多糖 の溶液中に浸漬することにより適用される、請求項13、14または17に記載の方法 。 19.インプラントの少なくとも組み込もうとする部分が、キトサンと、それに固 定された、ヘパリン、ヘパラン硫酸、コンドロイチン硫酸およびデキストラン硫 酸から選ばれる多糖とからなる、硬組織の再生を刺激する作用剤でコーティング されていることを特徴とする、硬組織内への組み込みを意図したインプラント。 20.チタンから構成されている、請求項19に記載のインプラント。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9402528A SE9402528D0 (sv) | 1994-07-19 | 1994-07-19 | Hårdvävnadsstimulerande med el |
SE9402528-5 | 1994-07-19 | ||
PCT/SE1995/000857 WO1996002259A1 (en) | 1994-07-19 | 1995-07-13 | Hard tissue stimulating agent |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10502664A true JPH10502664A (ja) | 1998-03-10 |
JP3492377B2 JP3492377B2 (ja) | 2004-02-03 |
Family
ID=20394768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50495596A Expired - Fee Related JP3492377B2 (ja) | 1994-07-19 | 1995-07-13 | 硬組織刺激剤 |
Country Status (22)
Country | Link |
---|---|
US (1) | US5894070A (ja) |
EP (1) | EP0771206B1 (ja) |
JP (1) | JP3492377B2 (ja) |
KR (1) | KR100395724B1 (ja) |
CN (1) | CN1081923C (ja) |
AT (1) | ATE219678T1 (ja) |
BR (1) | BR9508322A (ja) |
CA (1) | CA2194462C (ja) |
CZ (1) | CZ289981B6 (ja) |
DE (1) | DE69527203T2 (ja) |
DK (1) | DK0771206T3 (ja) |
ES (1) | ES2178675T3 (ja) |
FI (1) | FI970202A0 (ja) |
HU (1) | HU220770B1 (ja) |
IS (1) | IS1793B (ja) |
MX (1) | MX9700443A (ja) |
NO (1) | NO310223B1 (ja) |
NZ (1) | NZ290219A (ja) |
PL (1) | PL181764B1 (ja) |
RU (1) | RU2153877C2 (ja) |
SE (1) | SE9402528D0 (ja) |
WO (1) | WO1996002259A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004505678A (ja) * | 2000-08-10 | 2004-02-26 | オスファルマ エス.エル. | 高い細胞接着能を有するキトサン系フィルムの製造方法および用途、ならびに該フィルムを被覆した製品 |
JP4606586B2 (ja) * | 1998-11-10 | 2011-01-05 | 株式会社ネーテック | 機能性キトサン誘導体 |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9402528D0 (sv) * | 1994-07-19 | 1994-07-19 | Astra Ab | Hårdvävnadsstimulerande med el |
KR100237738B1 (ko) * | 1997-04-26 | 2000-01-15 | 이용찬 | 생채 매식용 의료기구 임플란트의 기능 향상방법 |
DE19724869C2 (de) * | 1997-06-12 | 1999-05-12 | Henkel Kgaa | Verwendung von Citosanderivaten zur Oberflächenbeschichtung |
EP0899247B1 (en) * | 1997-08-28 | 2002-11-06 | Ngk Spark Plug Co., Ltd | Calcium phosphate cement and calcium phosphate cement composition |
JP4215884B2 (ja) * | 1998-03-23 | 2009-01-28 | 日本特殊陶業株式会社 | リン酸カルシウムセメント及びリン酸カルシウムセメント組成物 |
US20030147860A1 (en) * | 2002-02-07 | 2003-08-07 | Marchosky J. Alexander | Compositions and methods for forming and strengthening bone |
US6306125B1 (en) | 1998-06-22 | 2001-10-23 | Neovasys, Inc. | Angiogenic implant delivery system and method |
FR2791262B1 (fr) * | 1999-03-22 | 2001-09-28 | Virbac Sa | Compositions a base de chondroitine et de chitosan pour la protection, le traitement ou le remplacement des tissus conjonctifs |
AU782394B2 (en) | 1999-06-29 | 2005-07-21 | J. Alexander Marchosky | Compositions and methods for forming and strengthening bone |
GB9920393D0 (en) * | 1999-08-27 | 1999-11-03 | Medix Scient Uk Limited | Plant extract mixtures and their uses |
FI19991852A (fi) | 1999-09-01 | 2001-03-01 | Yli Urpo Antti | Uusi monikerroksinen materiaali, joka käsittää vaikuttavan ainesosan, ja sen valmistus |
AU1375301A (en) * | 1999-11-15 | 2001-05-30 | Bio Syntech Canada Inc | Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution |
EP1255576B1 (en) * | 1999-12-09 | 2003-08-20 | Biosyntech Canada Inc. | Mineral-polymer hybrid composition |
US20030158302A1 (en) * | 1999-12-09 | 2003-08-21 | Cyric Chaput | Mineral-polymer hybrid composition |
DK1294414T3 (da) * | 2000-06-29 | 2006-07-24 | Biosyntech Canada Inc | Præparat og fremgangsmåde til heling og regenerering af brusk og andre væv |
DE60125973D1 (de) * | 2000-11-15 | 2007-02-22 | Biosyntech Canada Inc | Verfahren zur wiederherstellung einer geschädigten bandscheibe |
ES2353116T3 (es) * | 2002-07-16 | 2011-02-25 | Bio Syntech Canada Inc. | Composiciones para disoluciones de quitosano citocompatibles, inyectables, autogelificantes para encapsular y administrar células vivas o factores biológicamente activos. |
US20040054414A1 (en) | 2002-09-18 | 2004-03-18 | Trieu Hai H. | Collagen-based materials and methods for augmenting intervertebral discs |
FR2844717B1 (fr) * | 2002-09-23 | 2006-07-07 | Richard Cancel | Plaque de renfort comprenant notamment du chitosane |
JP2006515765A (ja) * | 2002-11-15 | 2006-06-08 | エスディージーアイ・ホールディングス・インコーポレーテッド | 滑膜性関節を治療するためのコラーゲンベース材料および方法 |
US20040186471A1 (en) * | 2002-12-07 | 2004-09-23 | Sdgi Holdings, Inc. | Method and apparatus for intervertebral disc expansion |
DE10338110A1 (de) * | 2003-08-15 | 2005-03-10 | Biomet Deutschland Gmbh | Mit Chitosan beschichteter metallischer Gegenstand sowie Verfahren zu dessen Herstellung |
WO2005065396A2 (en) * | 2003-12-31 | 2005-07-21 | Osteotech, Inc. | Improved bone matrix compositions and methods |
US20070231788A1 (en) * | 2003-12-31 | 2007-10-04 | Keyvan Behnam | Method for In Vitro Assay of Demineralized Bone Matrix |
FR2866571B1 (fr) * | 2004-02-20 | 2007-09-21 | Philippe Zanchetta | Utilisation d'un melange de polysaccharides specifiques denomme par l'inventeur ezbone, comprenant de l'acide hyaluronique, de la chondroitine 6 sulfate, du dermatane sulfate et de l'heparine en cicatrisation osseuse. |
AU2005239977B2 (en) * | 2004-05-07 | 2010-11-11 | The University Of Queensland | Composition for stimulating bone growth and differentiation and method for isolating same |
WO2005107772A1 (en) * | 2004-05-07 | 2005-11-17 | The University Of Queensland | Composition for stimulating bone growth and differentiation and method for isolating same |
CA2577447C (en) | 2004-08-16 | 2017-08-01 | Cellresearch Corporation Pte Ltd | Isolation of stem/progenitor cells from amniotic membrane of umbilical cord |
US20080118542A1 (en) * | 2005-01-19 | 2008-05-22 | Bonoss Medical Ab | Growth Factor Composition |
EP1937326B1 (en) | 2005-10-21 | 2018-09-12 | CellResearch Corporation Pte Ltd | Isolation and cultivation of stem/progenitor cells from the amniotic membrane of umbilical cord and uses of cells differentiated therefrom |
AU2006308534B2 (en) | 2005-11-01 | 2013-02-07 | Warsaw Orthopedic, Inc. | Bone matrix compositions and methods |
CA2628244A1 (en) * | 2005-11-04 | 2007-05-10 | Bio Syntech Canada Inc. | Gel formation of polyelectrolyte aqueous solutions by thermally induced changes in ionization state |
DE102006020035A1 (de) * | 2006-04-26 | 2007-10-31 | B. Braun Melsungen Ag | Herstellung und Verwendung von Poly(hydroxyethylstärke)chitin- und Poly(Carboxymethylstärke)chitin-Verbindungen |
US8399619B2 (en) * | 2006-06-30 | 2013-03-19 | Warsaw Orthopedic, Inc. | Injectable collagen material |
US8118779B2 (en) * | 2006-06-30 | 2012-02-21 | Warsaw Orthopedic, Inc. | Collagen delivery device |
EP1977739A1 (en) * | 2007-04-03 | 2008-10-08 | Bioiberica, S.A. | Nanoparticulate composition of chitosan and chondroitin sulfate |
US9554920B2 (en) * | 2007-06-15 | 2017-01-31 | Warsaw Orthopedic, Inc. | Bone matrix compositions having nanoscale textured surfaces |
EP3207948B1 (en) * | 2007-06-15 | 2020-02-26 | Warsaw Orthopedic, Inc. | Bone matrix compositions and methods |
AU2008265852B2 (en) * | 2007-06-15 | 2014-04-17 | Warsaw Orthopedic, Inc. | Method of treating tissue |
WO2008157492A2 (en) * | 2007-06-15 | 2008-12-24 | Osteotech, Inc. | Osteoinductive demineralized cancellous bone |
WO2009009684A1 (en) * | 2007-07-10 | 2009-01-15 | Osteotech, Inc. | Delivery system |
US20110054408A1 (en) * | 2007-07-10 | 2011-03-03 | Guobao Wei | Delivery systems, devices, tools, and methods of use |
ES2446544T3 (es) | 2007-10-19 | 2014-03-10 | Warsaw Orthopedic, Inc. | Composiciones de matrices óseas desmineralizadas y métodos |
GB2463474B (en) * | 2008-09-11 | 2012-05-02 | Agency Science Tech & Res | Therapeutic bone growth and regeneration |
US9101475B2 (en) * | 2009-02-12 | 2015-08-11 | Warsaw Orthopedic, Inc. | Segmented delivery system |
MX2014008404A (es) | 2012-01-27 | 2014-08-22 | Hoffmann La Roche | Quitosan enlazado covalentamente con antagonista de la integrina de molecula pequeña para suministro dirigido. |
EP3569262A1 (en) | 2013-03-14 | 2019-11-20 | Tricol Biomedical, Inc. | Biocompatible and bioabsorbable derivatized chitosan compositions |
CN105126165B (zh) * | 2015-01-21 | 2017-12-08 | 中国人民解放军第三〇七医院 | 一种钛牙种植体材料及其制备方法与应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL163522B (nl) * | 1970-07-20 | 1980-04-15 | Montedison Spa | Werkwijze om een katalysator te bereiden voor de polymerisatie van alkenen-1. |
US5510418A (en) * | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
US5256447A (en) * | 1991-12-31 | 1993-10-26 | Minnesota Mining And Manufacturing Company | Adhesive composition and method |
BR9207010A (pt) * | 1991-12-31 | 1995-12-05 | Minnesota Mining & Mfg | Composição adesiva e processo de aderência de um material restaurador a um substrato |
SE9402528D0 (sv) * | 1994-07-19 | 1994-07-19 | Astra Ab | Hårdvävnadsstimulerande med el |
-
1994
- 1994-07-19 SE SE9402528A patent/SE9402528D0/xx unknown
-
1995
- 1995-07-13 ES ES95926565T patent/ES2178675T3/es not_active Expired - Lifetime
- 1995-07-13 CA CA002194462A patent/CA2194462C/en not_active Expired - Fee Related
- 1995-07-13 EP EP95926565A patent/EP0771206B1/en not_active Expired - Lifetime
- 1995-07-13 DK DK95926565T patent/DK0771206T3/da active
- 1995-07-13 CN CN95195024A patent/CN1081923C/zh not_active Expired - Fee Related
- 1995-07-13 KR KR1019970700338A patent/KR100395724B1/ko not_active IP Right Cessation
- 1995-07-13 BR BR9508322A patent/BR9508322A/pt not_active Application Discontinuation
- 1995-07-13 US US08/505,353 patent/US5894070A/en not_active Expired - Lifetime
- 1995-07-13 CZ CZ1997140A patent/CZ289981B6/cs not_active IP Right Cessation
- 1995-07-13 JP JP50495596A patent/JP3492377B2/ja not_active Expired - Fee Related
- 1995-07-13 MX MX9700443A patent/MX9700443A/es unknown
- 1995-07-13 PL PL95318326A patent/PL181764B1/pl unknown
- 1995-07-13 DE DE69527203T patent/DE69527203T2/de not_active Expired - Lifetime
- 1995-07-13 WO PCT/SE1995/000857 patent/WO1996002259A1/en active IP Right Grant
- 1995-07-13 RU RU97102352/14A patent/RU2153877C2/ru active
- 1995-07-13 HU HU9700160A patent/HU220770B1/hu not_active IP Right Cessation
- 1995-07-13 NZ NZ290219A patent/NZ290219A/en unknown
- 1995-07-13 AT AT95926565T patent/ATE219678T1/de active
-
1997
- 1997-01-06 IS IS4409A patent/IS1793B/is unknown
- 1997-01-17 FI FI970202A patent/FI970202A0/fi unknown
- 1997-01-17 NO NO19970215A patent/NO310223B1/no unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4606586B2 (ja) * | 1998-11-10 | 2011-01-05 | 株式会社ネーテック | 機能性キトサン誘導体 |
JP2004505678A (ja) * | 2000-08-10 | 2004-02-26 | オスファルマ エス.エル. | 高い細胞接着能を有するキトサン系フィルムの製造方法および用途、ならびに該フィルムを被覆した製品 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10502664A (ja) | 硬組織刺激剤 | |
US4233360A (en) | Non-antigenic collagen and articles of manufacture | |
US4140537A (en) | Aqueous collagen composition | |
JP4033485B2 (ja) | 抗癒着剤 | |
JP4856309B2 (ja) | ヒアルロン酸誘導体を含んでいる三次元人工器官及びそれらの調製工程 | |
US6486140B2 (en) | Agents, and methods employing them, for the prevention or reduction of tissue adhesion at a wound site | |
WO2003084571A1 (fr) | Composition therapeutique destinee aux maladies infectieuses des os | |
CN107412861A (zh) | 重组胶原蛋白复合硫酸软骨素和聚乙二醇的骨修复凝胶 | |
JP2008527033A (ja) | 増殖因子組成物 | |
CN111298199B (zh) | 一种骨科临时植入体及其制备方法 | |
CN110665060B (zh) | 一种骨修复材料及其制备方法和应用 | |
AU696183C (en) | Hard tissue stimulating agent | |
RU2278679C1 (ru) | Способ получения материала для остеопластики и материал для остеопластики | |
RU2197974C1 (ru) | Биокомпозиционный материал для замещения костных дефектов | |
JPH0669486B2 (ja) | 生物学的機能を有するコラーゲン膜の製造法 | |
JP4726402B2 (ja) | 管腔形成誘導性材料 | |
CN117180489A (zh) | 一种微纤维胶原止血材料及其制备方法和应用 | |
RO131951A0 (ro) | Hidrogeluri bistratificate pe bază de componente ale matricei extracelulare şi polizaharide folosite în vindecarea osteocondrală |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071114 Year of fee payment: 4 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071114 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081114 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091114 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101114 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101114 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111114 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121114 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131114 Year of fee payment: 10 |
|
LAPS | Cancellation because of no payment of annual fees |